Chart of Day: Structure Therapeutics (GPCR) – 5/22

Keep an eye on Structure Therapeutics (SYM: GPCR).

According to JPMorgan, it’s an overlooked player in the weight loss treatment market. The firm has an overweight rating on the stock, with a price target of $65.


“We think the opportunity for oral GLP-1s is underappreciated and think this market could generate $30bn in sales by 2035,” added the firm, as quoted by CNBC. “GPCRs lead asset, 1290, is a pure-play option for this opportunity, and even a small share would support substantial upside to the stock.”

Helping, interest in weight loss medications is through the roof. In fact, according to Goldman Sachs, at current pace the market could be worth about $100 billion by 2030.

deal of the month

best growth stocks


Bundle package – lifetime subscriptions for all products


Recent posts


Connect with Us

Get FREE Daily Stock Tips

Join and receive market insider stock picks, trade alerts and unique investing insights
This field is for validation purposes and should be left unchanged.
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.

Join Waitlist

We’re sorry, but due to the popularity of our services, we have reached our max number of subscribers and are not currently accepting more. If spots become available, we will be sure to contact you. Please join the waitlist below.
Thank You!

"*" indicates required fields

This field is for validation purposes and should be left unchanged.